Changeflow GovPing Pharma & Drug Safety Cerebrospinal fluid kinetics of urolithin A study
Routine Notice Added Final

Cerebrospinal fluid kinetics of urolithin A study

Favicon for clinicaltrials.gov ClinicalTrials.gov
Published
Detected
Email

Summary

NIH/NLM published a clinical trial registration on ClinicalTrials.gov (NCT07517913) for a study examining the cerebrospinal fluid pharmacokinetics of urolithin A in approximately 12 healthy participants. The single-center, open-label study will assess how urolithin A distributes into cerebrospinal fluid following oral administration.

What changed

NIH/NLM registered a new clinical trial on ClinicalTrials.gov (NCT07517913) titled "Cerebrospinal fluid kinetics of urolithin A study." The trial will evaluate the pharmacokinetics of urolithin A in cerebrospinal fluid following oral administration in healthy adult participants. The single-center, open-label study plans to enroll approximately 12 subjects and is sponsored by Amazentis SA.

Healthcare researchers and supplement manufacturers monitoring urolithin A-related research should track this trial for data on whether orally administered urolithin A achieves measurable concentrations in cerebrospinal fluid, which would support further investigation into neurological applications of the compound.

What to do next

  1. Monitor for study completion and results posting on ClinicalTrials.gov
  2. Review results when published to assess implications for urolithin A supplement development

Archived snapshot

Apr 9, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Show glossary

Get daily alerts for ClinicalTrials.gov

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH/NLM.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
NIH/NLM
Published
March 1st, 2024
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
NCT07517913

Who this affects

Applies to
Patients Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Clinical trial registration Pharmacokinetics research
Geographic scope
United States US

Taxonomy

Primary area
Public Health
Operational domain
Clinical Operations
Compliance frameworks
GxP
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when ClinicalTrials.gov publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.